HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH ADULT PNEUMOCOCCAL DISEASE HOSPITALIZATIONS IN SPAIN: RESULTS FROM THE NATIONAL HOSPITAL DISCHARGE DATABASE
Author(s)
M. Doyinsola Bailey, BSc, MPH, PhD1, Silvia Fernández Soberón, MSc2, Antonio Lalueza, MD3, Marcos Valdés Álvarez, MSc4, Mónica Cerezales, PhD4, Helena Díaz Cuervo, PhD4, Ben Kahn, MPH, PhD1, Katherine Nelson, MPH, PhD1, Gonzalo Nocea, MSc2.
1Merck & Co., Inc., Rahway, NJ, USA, 2MSD Ltd, Madrid, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Axentiva Solutions SL, Oviedo, Spain.
1Merck & Co., Inc., Rahway, NJ, USA, 2MSD Ltd, Madrid, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Axentiva Solutions SL, Oviedo, Spain.
OBJECTIVES: To describe trends in invasive pneumococcal disease (IPD) and all-cause pneumonia (ACP) among adults in Spain and associated variation in clinical outcomes and healthcare resource utilization (HCRU).
METHODS: Adults hospitalized with IPD or ACP from 2016-2023 were identified using ICD-10 codes in the national hospital discharge database (RAE-CMBD). Analyses were stratified by age (18-49, 50-59, 60-64, ≥65 years) and by IPD risk groups. Outcomes included annual incidence rates (IR; per 100,000 people), hospital length of stay (LoS; days), ICU admission rate (%), ICU length of stay (ICU LoS; days) and mean and total hospitalization costs (€), including inpatient and ICU care. Group differences are presented descriptively.
RESULTS: From 2016 to 2023, 25,510 IPD (IR=8.1) and 1,562,427 ACP (IR=502.0) hospitalizations were identified. IPD incidence declined during 2020-2021 and increased afterwards, while ACP incidence peaked during 2020-2021. The highest observed incidence was in adults ≥65 years (IPD IR=21.1 vs. 8.1 overall; ACP IR=1509.0 vs. 502.0 overall) and decreased across younger age groups.Middle-aged adults (50-59 and 60-64 years) experienced higher per-patient burden versus overall, for both ICP and ACP, including LoS (IPD: 17.1-17.3 vs. 14.9 days; ACP: 12.0-12.8 vs. 11.1 days), ICU LoS (IPD: 5.0-5.3 vs. 3.4 days; ACP: 2.2-2.5 vs.1.2 days) and mean costs per-hospitalization (IPD: €12-13K vs. €10K; ACP: €7.8-8.3K vs. €6.5K).By risk group, immunodeficient adults exhibited high IPD incidence (IR=1084.0) and, by risk condition, adults with HIV had high per-patient costs (€13K), while chronic respiratory and cardiovascular disease contributed the highest total costs (€178M).
CONCLUSIONS: Following pandemic-related declines, IPD incidence exceeded pre-pandemic levels, remaining consistently highest in adults ≥65 years. However, a substantial per-patient burden was also observed in middle-aged and high-risk adults, highlighting opportunities to optimize prevention beyond older adults and reduce the broader clinical and economic impact of pneumococcal disease.
METHODS: Adults hospitalized with IPD or ACP from 2016-2023 were identified using ICD-10 codes in the national hospital discharge database (RAE-CMBD). Analyses were stratified by age (18-49, 50-59, 60-64, ≥65 years) and by IPD risk groups. Outcomes included annual incidence rates (IR; per 100,000 people), hospital length of stay (LoS; days), ICU admission rate (%), ICU length of stay (ICU LoS; days) and mean and total hospitalization costs (€), including inpatient and ICU care. Group differences are presented descriptively.
RESULTS: From 2016 to 2023, 25,510 IPD (IR=8.1) and 1,562,427 ACP (IR=502.0) hospitalizations were identified. IPD incidence declined during 2020-2021 and increased afterwards, while ACP incidence peaked during 2020-2021. The highest observed incidence was in adults ≥65 years (IPD IR=21.1 vs. 8.1 overall; ACP IR=1509.0 vs. 502.0 overall) and decreased across younger age groups.Middle-aged adults (50-59 and 60-64 years) experienced higher per-patient burden versus overall, for both ICP and ACP, including LoS (IPD: 17.1-17.3 vs. 14.9 days; ACP: 12.0-12.8 vs. 11.1 days), ICU LoS (IPD: 5.0-5.3 vs. 3.4 days; ACP: 2.2-2.5 vs.1.2 days) and mean costs per-hospitalization (IPD: €12-13K vs. €10K; ACP: €7.8-8.3K vs. €6.5K).By risk group, immunodeficient adults exhibited high IPD incidence (IR=1084.0) and, by risk condition, adults with HIV had high per-patient costs (€13K), while chronic respiratory and cardiovascular disease contributed the highest total costs (€178M).
CONCLUSIONS: Following pandemic-related declines, IPD incidence exceeded pre-pandemic levels, remaining consistently highest in adults ≥65 years. However, a substantial per-patient burden was also observed in middle-aged and high-risk adults, highlighting opportunities to optimize prevention beyond older adults and reduce the broader clinical and economic impact of pneumococcal disease.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
RWD47
Topic
Real World Data & Information Systems
Disease
Infectious Disease (non-vaccine), Vaccines